Chemours Company (The) (CC) Stock Price & How to Invest

Last updated November 2026

Short answer

Chemours (NYSE: CC) is a US specialty chemicals maker known for TiO2 pigment, Opteon refrigerants, and fluoropolymers. As of November 20, 2026 it trades near $11.27 with a market cap of roughly $1.7 billion, a cyclical, litigation-shadowed value name where the refrigerant franchise is the growth story and PFAS liabilities and a heavy debt load are the overhang.

CC stock price

As of 2026-11-20, Chemours Company (The) (CC) last closed at $10.88, down 1.5% over the past year. Over the past 52 weeks it has traded between $10.88 and $27.94.

CC last close
$10.88
1 day
-7.80%
1 month
-15.92%
1 year
-1.54%
52-week range
$10.88 to $27.94
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Chemours Company (The)'s investor relations page. Walnut is informational, not investment advice.

CC key stats

At $10.88 on November 20, 2026, Chemours Company (The) (CC) has a market cap of $1.6B and a dividend yield of 3.22%.

Market cap
$1.6B
P/E (forward)
6.3
Price to book
10.6
Dividend yield
3.22%
Beta
1.47

Market cap, P/E and yield are measured at the $10.88 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Chemours Company (The) (CC)?

The last two weeks for Chemours Company (The), as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • CC closed at $10.88 on November 20, 2026, down 18.1% over the past five trading days (from $13.29).
  • On November 18, 2026, Chemours Company (The) filed an 8-K with the SEC reporting a change in its directors or officers (Item 5.02). Read the 8-K on sec.gov
  • On November 9, 2026, JP Morgan lowered its target to $14.00 from $15.00 (Neutral).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Chemours Company (The) (CC) do?

The Chemours Company is a US-listed specialty chemicals producer spun out of DuPont in 2015. It reports through three segments: Thermal & Specialized Solutions (refrigerants and thermal management, led by the Opteon low-global-warming-potential product line), Titanium Technologies (TiO2 white pigment used in paints, plastics, and paper), and Advanced Performance Materials (high-end fluoropolymers and advanced materials). Trailing twelve-month revenue is roughly $5.84 billion, about the same as full-year 2025, and the company operates globally across industrial, construction, automotive, and electronics end markets with about 5,700 employees.

The investment picture is a barbell. Opteon refrigerants are benefiting from the regulatory phase-down of higher-emission HFCs under the AIM Act, giving Chemours a structurally growing, higher-margin franchise. Against that, the Titanium Technologies business is deeply cyclical and has faced soft pricing and demand tied to construction and coatings, while the company carries substantial, widely reported PFAS environmental and litigation liabilities. Chemours reached a roughly $450 million federal PFAS settlement with the EPA earlier in 2026, and in September 2026 Chemours, DuPont, and Corteva agreed a $455 million settlement with North Carolina and 11 local entities over Fayetteville Works discharges, paid over 15 years. AFFF multi-district litigation and other claims remain unresolved, keeping the balance sheet and legal exposure central to how the stock trades.

The third quarter of 2026, reported in early November, brought net sales of about $1.54 billion, up about 3 percent year over year, and GAAP net income of about $196 million, but adjusted EPS of $0.21 missed the $0.26 consensus. The mix flipped from earlier in the year: Titanium Technologies sales rose about 11 percent on roughly 10 percent higher pricing, while Thermal & Specialized Solutions sales fell about 9 percent as North American air-conditioning aftermarket demand for Opteon weakened. Adjusted EBITDA was about $200 million, and management guided full-year 2026 adjusted EBITDA to $775 million to $800 million. Chemours also launched Faizeon, a line of two-phase liquid cooling fluids for AI data centers, and named Amy Rocklin general counsel on the retirement of Kristine Wellman. The stock kept sliding after the report: as of November 20, 2026 it closed at $11.27, down about 8 percent year to date and about 28 percent over three months but up about 7 percent over one year. RBC had downgraded the shares in October on TiO2 weakness, cutting its target to $14 from $22.

What's driving Chemours Company (The) (CC)?

1. Opteon refrigerant growth

The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. Regulatory HFC phase-downs under the AIM Act and similar rules abroad are shifting demand toward the newer chemistries Chemours produces. Near-term momentum has cooled: third-quarter 2026 segment sales fell about 9 percent to $510 million and segment adjusted EBITDA fell about 30 percent to $136 million, against a strong prior-year quarter in North American stationary air conditioning. In November Chemours launched Faizeon, five two-phase dielectric cooling fluids for direct-to-chip and immersion cooling in AI and high-density data centers, a new outlet for its fluorochemistry. Analysts on average expect 2026 revenue of about $5.93 billion, rising to about $6.14 billion in 2027.

2. TiO2 pigment cyclical recovery

Titanium Technologies is the largest revenue segment and is highly sensitive to construction, coatings, and industrial demand. After pricing pressure through the first half of 2026, the third quarter turned: segment sales rose about 11 percent to $680 million on roughly 10 percent higher pricing, and adjusted EBITDA more than tripled to about $85 million, a 13 percent margin. Persistent TiO2 weakness had been the stated reason for RBC's October downgrade, so whether that pricing holds through a seasonally weaker fourth quarter (segment EBITDA guided at $60 million to $65 million) is a key test. Consolidated margins remain thin, with operating margin near 3 percent on a trailing basis.

3. Cost, cash flow, and dividend

Chemours has emphasized cost discipline, capital-expenditure control, and free cash flow conversion. Third-quarter free cash flow was about $98 million, and trailing EBITDA is about $488 million; management targets 2026 free cash flow conversion above 15 percent and net leverage below 4.2 times by year-end, from about 4.3 times at September 30. The company pays a dividend of about $0.35 per share annually, a yield near 3.0 percent at the current price, which is high relative to its GAAP losses. Leverage is the constraint: about $3.9 billion of gross debt against roughly $698 million of cash.

4. PFAS liability resolution

Progress on resolving PFAS exposure is itself a potential catalyst. The federal EPA settlement of about $450 million and the September 2026 North Carolina settlement of $455 million (Chemours pays half under a 2021 cost-sharing agreement with DuPont and Corteva, roughly $50 million expected over the next 12 months) removed some uncertainty at legacy sites. Further settlements or favorable outcomes in the remaining AFFF litigation could reduce the discount the market applies, though the timing and size of remaining liabilities are uncertain. In the third quarter, Chemours collected about $150 million of PFAS insurance proceeds and made about $100 million of settlement payments. A large November 2026 PFAS settlement by 3M, reported at $7.35 billion, is a reminder of the size such claims can reach across the industry.

What are the risks to Chemours Company (The) (CC)?

PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. The Titanium Technologies segment is cyclical and exposed to weak construction and coatings demand plus low-cost pigment competition, although pigment pricing improved in the third quarter of 2026. The refrigerant business has its own cyclicality, with Opteon volumes down about 9 percent in that quarter. The company posted GAAP net losses in the three quarters before the third, including about $274 million in Q2 2026, and still has a trailing net loss of about $154 million. Gross debt of about $3.9 billion, net leverage near 4.3 times, and the cash demands of legal settlements constrain financial flexibility, and the dividend currently exceeds GAAP earnings. Regulatory, raw-material, and currency swings add further volatility to results. Walnut is not an investment adviser; this page describes the business and is not a recommendation.

What is the Chemours Company (The) (CC) forecast?

10 analysts publish price targets on CC, averaging $16.00 as of November 2026, or +47.1% against the $10.88 share price on November 20, 2026. The published targets run from $14.00 to $18.00, a narrow spread, and the ratings split 2 buy, 8 hold, 0 sell. Over the last six months there have been 0 raises and 11 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is CC a buy or a sell?

We give no verdict on Chemours Company (The). Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Opteon refrigerant growth. The Thermal & Specialized Solutions segment, anchored by Opteon low-GWP refrigerants, is Chemours' clearest growth engine. The most optimistic published target, $18.00, assumes this works close to its best case.

The case against. PFAS environmental litigation and remediation are the defining risk: Chemours faces thousands of personal injury claims in the AFFF multi-district litigation with bellwether trials that could produce unpredictable damages, on top of the federal and North Carolina settlements already reached in 2026. The most pessimistic target, $14.00, is roughly what CC is worth if this bites instead.

Read the full bull and bear case on CC, including what would have to change to break either one. Walnut is not an investment adviser.

Has Chemours Company (The) (CC) split its stock?

No. Chemours Company (The) (CC) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Chemours Company (The) (CC) valued?

Market cap, P/E and dividend yield at today's price are in the CC key stats above. The business figures below come from Chemours Company (The)'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$5.84B
  • Revenue growth (Q3 2026, YoY): ~+3% (~$1.54B)
  • Net income (TTM): ~-$154M (Q3 2026 GAAP ~+$196M)
  • Q3 2026 adj. EPS vs est.: $0.21 vs $0.26
  • Adjusted EBITDA (FY2026 guidance): ~$775M-$800M

As of November 2026: At about $11.27 a share on November 20, 2026, Chemours is valued at roughly $1.7 billion, or about 0.29 times its ~$5.84 billion revenue, a cyclical-and-litigation discount rather than a growth multiple. There is no trailing P/E because of GAAP losses, while the forward P/E of about 6.5 rests on analysts' 2027 EPS estimate of about $1.72 roughly doubling 2026's ~$0.81. EV/EBITDA near 10.6 shows how much of the enterprise value sits in about $3.9 billion of gross debt; consensus for the fourth quarter is EPS of about $0.14 on revenue of about $1.42 billion.

Who competes with Chemours Company (The) (CC)?

TiO2 pigment producers

In Titanium Technologies, Chemours competes with dedicated pigment makers such as Tronox (TROX) and Kronos Worldwide (KRO), plus lower-cost international producers. This is a commoditized, capital-intensive market where scale and cost position drive returns.

Refrigerants and fluoroproducts

In Thermal & Specialized Solutions, Honeywell is the primary rival in low-GWP refrigerants, with the two firms alternating between litigation and licensing over HFO intellectual property. Daikin and Arkema are also significant fluorochemical players.

Advanced fluoropolymers and materials

In Advanced Performance Materials, Chemours competes with diversified specialty and fluoromaterials companies including Daikin, Syensqo (formerly part of Solvay), Arkema, and 3M's legacy fluoromaterials operations for high-performance polymer applications.

What stocks are similar to Chemours Company (The) (CC)?

Other names that sit close to CC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Chemours Company (The) (CC)

There are three common ways to get CC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Chemours Company (The) (CC)

CC is a cyclical chemicals company with a genuine refrigerant growth engine, a pigment business that is finally pricing higher, a GAAP net loss over the last twelve months, about $3.9 billion of gross debt, and sizable PFAS liabilities. The third-quarter report in early November missed on adjusted EPS as Opteon volumes fell, and the shares are down about 8 percent in 2026 and roughly 28 percent over the past three months, though still up about 7 percent over one year.

More on Chemours Company (The) (CC)

Whether CC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CC a buy or a sell?, and where the stock could go from here in the CC stock forecast.

For income investors, whether CC pays a dividend and how the payout looks is covered in does CC pay a dividend? And to weigh CC against a peer, read the full side-by-side comparisons: CC vs HON and CC vs WDFC.

Wondering how CC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Chemours Company (The)

Ask Walnut's AI anything about CC and see how it fits what you own.

FAQ

What does Chemours do?

+

Chemours is a US specialty chemicals company that makes TiO2 white pigment, Opteon low-global-warming-potential refrigerants, and advanced fluoropolymers. It was spun out of DuPont in 2015 and sells into coatings, plastics, refrigeration, automotive, and industrial markets worldwide.

What are Chemours' business segments?

+

The company reports three segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO2 pigment), and Advanced Performance Materials (fluoropolymers and advanced materials), plus a smaller Performance Chemicals and Intermediates business.

How much revenue does Chemours generate?

+

Chemours reported full-year 2025 net sales of roughly $5.8 billion, about flat versus 2024, and trailing twelve-month revenue through the third quarter of 2026 is about $5.84 billion. Quarterly revenue was about $1.38 billion in Q1 2026, $1.59 billion in Q2 and $1.54 billion in Q3, when sales were up about 3 percent year over year. Management expects full-year 2026 net sales growth of about 2 percent.

Is Chemours profitable?

+

Not on a trailing GAAP basis. Chemours reported net losses of about $47 million in Q4 2025, $29 million in Q1 2026, and $274 million in Q2 2026, then GAAP net income of about $196 million in Q3 2026, for a trailing net loss of about $154 million. Adjusted results are positive (Q3 2026 adjusted EPS was $0.21), and analysts expect adjusted EPS of about $0.81 for 2026 and $1.72 for 2027.

What is the PFAS litigation about?

+

Chemours faces environmental claims tied to PFAS, or forever chemicals, from legacy manufacturing. In 2026 it reached a roughly $450 million federal settlement with the EPA, and in September 2026 it joined DuPont and Corteva in a $455 million settlement with North Carolina and 11 local entities over Fayetteville Works, with Chemours paying half. It still faces thousands of personal injury claims in the AFFF multi-district litigation with uncertain outcomes. In the third quarter of 2026 it received about $150 million of PFAS insurance proceeds and paid about $100 million in settlements.

Does Chemours pay a dividend?

+

Yes. Chemours pays a quarterly cash dividend of about $0.0875 per share, or roughly $0.35 annually. After the stock's decline, that works out to a yield near 3.0 percent as of November 20, 2026. Because the company has a trailing GAAP loss, the payout ratio on reported earnings is far above 100 percent, so the dividend relies on cash flow rather than net income.

Who are Chemours' main competitors?

+

In TiO2 pigment it competes with Tronox and Kronos Worldwide. In refrigerants its chief rival is Honeywell, alongside Daikin and Arkema. In advanced fluoropolymers it competes with Daikin, Syensqo, Arkema, and legacy 3M fluoromaterials.

What is the growth driver for Chemours?

+

The clearest growth driver is the Opteon low-GWP refrigerant line, which benefits from regulatory phase-downs of higher-emission HFCs under the AIM Act and comparable rules internationally. Opteon volumes fell in the third quarter of 2026 against a strong prior year, but the regulatory shift remains the main support for analysts' expectations of revenue rising to about $6.14 billion in 2027. Chemours is also pitching Faizeon two-phase cooling fluids, launched in November 2026, at AI data centers.

How did Chemours do in its latest quarter?

+

In Q3 2026 Chemours reported net sales of about $1.54 billion, up about 3 percent, and adjusted EPS of $0.21, below the $0.26 consensus, as Opteon refrigerant volumes fell about 9 percent. Titanium Technologies was the bright spot, with sales up about 11 percent and segment EBITDA more than tripling on higher pricing. GAAP net income was about $196 million. For the fourth quarter, management expects sales to fall 5 to 10 percent sequentially and adjusted EBITDA of $160 million to $185 million.

How has CC stock performed in 2026?

+

As of the November 20, 2026 close of $11.27, Chemours shares were down about 8 percent year to date and about 28 percent over the past three months, but up about 7 percent over one year. The 52-week range is roughly $10.51 to $28.67. Analysts' average rating is hold, with a mean target near $16 across ten analysts; RBC cut its rating and target in October on TiO2 weakness.

What is Chemours Faizeon?

+

Faizeon is a line of two-phase liquid cooling fluids Chemours launched in November 2026 for AI, high-performance computing and high-density data centers. It includes four products for direct-to-chip cooling and one for full-server immersion; the fluids absorb heat by boiling into vapor. Chemours cites third-party testing in which a Faizeon 200 system kept GPU temperatures up to 19 degrees C lower than a water-based single-phase system.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Chemours Company (The)'s investor relations page or your broker before making investment decisions.